The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

Technology can be harnessed to design novel and enhanced molecules that address challenges in biotechnology or medicine. Australian researchers, including those at the Charles Perkins Centre at the ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 3.8% in the morning session after the U.S. Food ...

The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 ...

In this episode presented by Eclipsebio, BioSpace's head of insights Lori Ellis discusses mRNA and srRNA with Andy Geall of Replicate Bioscience and Alliance for mRNA Medicines, and Pad Chivukula of ...

Moderna, Inc. (MRNA) on Thursday announced that the U.S. Food and Drug Administration (FDA) has fully approved its COVID-19 ...

Moderna (MRNA) stock rises as the company's Spikevax COVID-19 vaccine gets FDA approval for kids 6 months-11 years at higher ...

In an interview with The News & Observer, Dr. Barton Haynes discusses the future of HIV vaccine development after HHS ...

Institutions like OMRF have had almost unbroken bipartisan support as a national biomedical research policy. Breaking it ...

A Pennsylvania Representative is looking to ban testing mRNA vaccines on domestic animals. Representative Jacob Banta (R-Erie ...

Moderna Inc. jumped by 8.83 percent on Tuesday to close at $32.54 apiece as investor sentiment was boosted by a lawsuit filed ...